Chardan Capital Initiates Coverage On Gossamer Bio with Buy Rating, Announces Price Target of $160
Chardan Capital analyst Andreas Argyrides initiates coverage on Gossamer Bio (NASDAQ:GOSS) with a Buy rating and announces Price Target of $160.
Share
Why It Matters
A stock expert thinks Gossamer Bio is worth buying right now. When experts pick a stock, watch if the company keeps doing well.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.